Key Highlights

● Second-quarter revenue was $22.97 billion, up 48%, on volume growth of 60%.

● Realised prices fell 13%, partly offsetting the volume increase.

● 2026 revenue guidance was raised to $85.0 billion to $87.0 billion.

● Non-GAAP EPS guidance is $35.50 to $36.50, against a prior ceiling of $37.00.

Eli Lilly and Company (NYSE:LLY) reported second-quarter 2026 revenue of $22.97 billion on 5 August, up 48 per cent from $15.56 billion. The company attributed the rise to volume growth of 60 per cent, partly offset by a 13 per cent fall in realised prices. United States revenue rose 33 per cent to $14.4 billion, while revenue outside the United States rose 80 per cent to $8.6 billion. Overseas revenue also included a $250 million Jardiance sales milestone from partner Boehringer Ingelheim. Reported earnings per share were $7.94, up 26 per cent, and non-GAAP earnings per share were $8.38, up 33 per cent. Both figures include acquired in-process research and development charges of $3.03 per share, against $0.14 a year earlier.

Volume up, prices down

Two products dominated. Mounjaro revenue was $9.94 billion, up 91 per cent, and Zepbound was $4.93 billion, up 46 per cent. Within Mounjaro, the United States contributed $4.8 billion, up 45 per cent, and the rest of the world $5.2 billion, up 172 per cent. The pricing detail matters. Volume rose 37 per cent in the United States and 113 per cent elsewhere.

In the United States, realised prices fell 3 per cent, and the company said they would have fallen about 9 per cent excluding rebate and discount adjustments. Outside the United States prices fell 36 per cent, mainly because Mounjaro was added to China's national reimbursement drug list. The release also refers to previously announced reductions in Zepbound cash-pay prices. Lilly's gross margin was 85.8 per cent on a reported basis, and research and development spending rose 14 per cent to $3.82 billion.

Raised guidance, trimmed EPS ceiling

Guidance is the company's own. Lilly now expects 2026 revenue of $85.0 billion to $87.0 billion, raised from $82 billion to $85 billion, and a performance margin of 49.0 to 50.5 per cent, up from 47.0 to 48.5 per cent. Non-GAAP earnings per share guidance is $35.50 to $36.50, against $35.50 to $37.00 previously. Lilly said underlying growth added $2.78 at the midpoint, which the $3.03 second-quarter charge more than offset. The range excludes charges of that kind incurred after 30 June. The tax rate is expected to remain between 18 and 19 per cent.

Pipeline milestones

The pipeline provided further news. Lilly reported three additional positive Phase 3 obesity trials for retatrutide and said the clinical data package is complete for obesity, obstructive sleep apnoea and knee osteoarthritis pain, with a submission to the US Food and Drug Administration planned for the first quarter of 2027. Orforglipron, marketed as Foundayo, generated $98 million in its first reported quarter and has been submitted in the United States for type 2 diabetes. Kisunla revenue was $167 million, up from $49 million, and Ebglyss was $201 million, up 131 per cent. Lilly also committed a further $4.5 billion to expand its Indiana manufacturing sites and completed acquisitions of Orna, Ajax, Centessa and Kelonia during the quarter. Chair and chief executive David Ricks said Lilly's momentum continues.

Volume Drives the Quarter as Pricing Pressure and Acquisition Charges Weigh

The release lists material risks. These include pricing pressure and government action on drug prices, intense competition, dependence on a small number of products, supply and manufacturing disruption, patent expiry, tariffs and litigation. Marketing, selling and administrative expenses rose 25 per cent to $3.43 billion, and acquisition charges can move earnings sharply from one quarter to another. The quarter shows volume doing the work that price is no longer doing, so the pace of volume growth is the key figure. Dividends paid were $1.73 per share, up 15 per cent.